Fexofenadine


Description

Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine. Fexofenadine, like other second and third-generation anti...

Read more

Pharmacology

Indication

For management of Seasonal allergic rhinitis

Pharmacodynamic

Fexofenadine is a second-generation, long lasting H1-receptor antagonist (antihistamine) which has a... Read more

Mechanism of action

Like other H1-blockers, Fexofenadine competes with free histamine for binding at H1-receptors in the... Read more

Absorption

33%

Protein binding

60%-70%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

14.4 hours

Route of elimination

Information currently not available.

Toxicity

Side effects include dizziness, drowsiness, and dry mouth.


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Headache US
  • adolescent
  • adult
  • Kind: experimental
    • Percent: 10.3%
  • Kind: placebo
    • Percent: 7.2%
  • Clinical Trial
    Headache US
  • Kind: experimental
    • Percent: 4.8%
  • Kind: placebo
    • Percent: 3.3%
  • Clinical Trial
    Dyspepsia US
  • Kind: experimental
    • Percent: 4.7%
  • Kind: placebo
    • Percent: 4.4%
  • Clinical Trial
    Upper Respiratory Tract Infection US
    • pediatric
  • Kind: experimental
    • Percent: 4.3%
  • Kind: placebo
    • Percent: 1.7%
  • Clinical Trial
    Coughing US
    • pediatric
  • Kind: experimental
    • Percent: 3.8%
  • Kind: placebo
    • Percent: 1.3%
  • Clinical Trial
    Otitis Media US
    • pediatric
  • Kind: experimental
    • Percent: 3.6%
  • Kind: placebo
    • Percent: 3.3%
  • Clinical Trial
    Cough US
    • pediatric
  • Kind: experimental
    • Percent: 3.6%
  • Kind: placebo
    • Percent: 3.3%
  • Clinical Trial
    Diarrhea US
    • pediatric
  • Kind: experimental
    • Percent: 3.0%
  • Kind: placebo
    • Percent: 2.6%
  • Clinical Trial
    Accidental injury US
    • pediatric
  • Kind: experimental
    • Percent: 2.9%
  • Kind: placebo
    • Percent: 1.3%
  • Clinical Trial
    Myalgia US
  • Kind: experimental
    • Percent: 2.6%
  • Kind: placebo
    • Percent: 2.2%
  • Clinical Trial
    Back Pain US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 2.5%
  • Kind: placebo
    • Percent: 1.4%
  • Clinical Trial
    Fever US
    • pediatric
  • Kind: experimental
    • Percent: 2.4%
  • Kind: placebo
    • Percent: 0.9%
  • Clinical Trial
    Pain US
    • pediatric
  • Kind: experimental
    • Percent: 2.4%
  • Kind: placebo
    • Percent: 0.4%
  • Clinical Trial
    Otitis Media US
    • pediatric
  • Kind: experimental
    • Percent: 2.4%
  • Kind: placebo
    • Percent: 0.0%
  • Clinical Trial
    Nasopharyngitis US
  • Kind: experimental
    • Percent: 2.4%
  • Kind: placebo
    • Percent: 2.2%
  • Clinical Trial
    Upper Respiratory Tract Infection US
  • Kind: experimental
    • Percent: 2.4%
  • Kind: placebo
    • Percent: 2.2%
  • Clinical Trial
    Back Pain US
  • Kind: experimental
    • Percent: 2.1%
  • Kind: placebo
    • Percent: 1.1%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 2.1%
  • Kind: placebo
    • Percent: 1.1%
  • Clinical Trial
    Pain in extremity US
  • Kind: experimental
    • Percent: 2.1%
  • Kind: placebo
    • Percent: 0.0%
  • Clinical Trial
    Rhinorrhea US
    • pediatric
  • Kind: experimental
    • Percent: 1.9%
  • Kind: placebo
    • Percent: 0.9%
  • Clinical Trial
    Dysmenorrhea US
    • adolescent
    • adult
  • Kind: experimental
    • Percent: 1.5%
  • Kind: placebo
    • Percent: 0.3%
  • Clinical Trial
    Somnolence US
    • pediatric
  • Kind: experimental
    • Percent: 1.1%
  • Kind: placebo
    • Percent: 0.2%
  • Clinical Trial
    Insomnia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Paranoia US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Sleep Disorders US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Nervousness US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Pruritus US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Urticaria US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Rash US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Hypersensitivity US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Angioedema US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Chest tightness US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Dyspnea US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Flushing US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing
    Anaphylaxis US
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial Post Marketing

    Contraindications

    Information currently not available.

    Food Interactions

    • Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly decrease serum levels of this product.
    • Take without regard to meals.

    Interactions

    Type in a drug name to check for interaction with Fexofenadine

    2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Fexofenadine.
    2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Fexofenadine.
    4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Fexofenadine.
    The risk or severity of adverse effects can be increased when Fexofenadine is combined with 4-Methoxyamphetamine.
    The risk or severity of adverse effects can be increased when Fexofenadine is combined with 5-methoxy-N,N-dimethyltryptamine.
    The risk or severity of adverse effects can be increased when Fexofenadine is combined with 7-Nitroindazole.
    The risk or severity of adverse effects can be increased when Fexofenadine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
    The serum concentration of Abemaciclib can be increased when it is combined with Fexofenadine.
    The risk or severity of QTc prolongation can be increased when Fexofenadine is combined with Abexinostat.
    The serum concentration of Acebutolol can be increased when it is combined with Fexofenadine.
    The risk or severity of adverse effects can be increased when Fexofenadine is combined with Acepromazine.
    The risk or severity of adverse effects can be increased when Fexofenadine is combined with Aceprometazine.
    The serum concentration of Fexofenadine can be increased when it is combined with Acetaminophen.
    The risk or severity of adverse effects can be increased when Acetazolamide is combined with Fexofenadine.
    The risk or severity of adverse effects can be increased when Fexofenadine is combined with Acetophenazine.
    The excretion of Fexofenadine can be decreased when combined with Acetylcysteine.
    Fexofenadine may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.
    The risk or severity of adverse effects can be increased when Fexofenadine is combined with Acetylglycinamide chloral hydrate.
    The serum concentration of Acetylsalicylic acid can be increased when it is combined with Fexofenadine.
    Fexofenadine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.

    References

    • 1 . Smith SM, Gums JG: Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22. doi: 10.1517/17425250903044967. [PubMed: 19545214]
    • 2 . Bachert C: A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. doi: 10.1016/j.clinthera.2009.05.017. [PubMed: 19539095]
    • 3 . Markham A, Wagstaff AJ: Fexofenadine. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. [PubMed: 9506246]
    • 4 . Golightly LK, Greos LS: Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs. 2005;65(3):341-84. [PubMed: 15669879]
    • 5 . Molimard M, Diquet B, Benedetti MS: Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. [PubMed: 15312146]

    Recent Questions